Cas:35180-14-4 2-benzyl-2,3-dihydro-1h-isoindole manufacturer & supplier

We serve Chemical Name:2-benzyl-2,3-dihydro-1h-isoindole CAS:35180-14-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-benzyl-2,3-dihydro-1h-isoindole

Chemical Name:2-benzyl-2,3-dihydro-1h-isoindole
CAS.NO:35180-14-4
Synonyms:N-Benzyl-isoindolin;2-Benzyl-isoindolin;2-benzyl-isoindoline;N-benzylisoindoline;2-benzyl-1,3-dihydro-isoindole
Molecular Formula:C15H15N
Molecular Weight:209.28600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:303.6ºC at 760 mmHg
Density:1.113g/cm3
Index of Refraction:1.626
PSA:3.24000
Exact Mass:209.12000
LogP:3.14030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-Benzyl-isoindolin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-benzyl-1,3-dihydro-isoindole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Benzyl-isoindolin Use and application,2-benzyl-1,3-dihydro-isoindole technical grade,usp/ep/jp grade.


Related News: The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021. 3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxypropanamide manufacturers According to the Food and Drug Administration and the Orphan Drug Designation program, orphan status applies to drugs and biologics defined as “those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the US, or that affect more than 200,000 people, styrene, sodium salt suppliers The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021. 1-bromo-4-(1-(4-methoxyphenyl)cyclopentyl)benzene vendor & factory In addition, the government has made a series of new commitments, including:,During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.